Obesity Medicine

EASD 2024: Amycretin was also found to be safe and well tolerated in adults with obesity and without diabetes.

Your daily dose of the clinical news you may have missed.

EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.

Once-daily oral TERNS-601 was associated with a significant mean 5% weight reduction after 28 days and had a favorable tolerability profile.

Your daily dose of the clinical news you may have missed.

In a study of adolescents with obesity, symptoms of depression and eating disorders decreased over the course of a 52-week intensive behavioral intervention.

Vials of tirzepatide 2.5 mg and 5 mg will be available with a prescription for the labeled drug through LillyDirect after completing a multistep verification process, the company said.

Patients with obesity face both physical and emotional challenges during the COVID-19 pandemic. How can PCPs help?

Results of the 3-year SURMOUNT-1 study reflect the longest trial to date of tirzepatide in adults with overweight/obesity and risk for developing T2D.

Your daily dose of the clinical news you may have missed.

Incretin analogues, an oral glucose formulation that targets endogenous nutrient-sensing pathways and a cannabinoid receptor 1 antagonist are in the new mix.

Semaglutide bought online without a prescription were unregistered, contaminated, and had levels of product that exceeded labeled amount, according to new data.

Tirzepatide reduced the risk of severe heart failure outcomes by 38% and drove weight loss of 15.7% in adults with HFpEF and obesity, with and without T2D..

The significant rise in new GLP-1 RA prescriptions between 2011 and 2023 saw a doubling in the proportion written for obesity and a decline in those for T2D.

Your daily dose of the clinical news you may have missed.

Get details on the relationship between obesity and mental health conditions, chronic pain, and hypertension, here.

Adiposity before age 60 to 64 years, beginning as early as age 20 years, was associated with adverse cardiac structure and function not explained by current BMI.

The oral GLP-1 RA was associated with weight loss of 7.3% in just 4 weeks and is designed with unique properties that will enhance multiple outcomes, Roche said.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Tirzepatide-treated participants were 3 times more likely than those treated with semaglutide to reach weight loss of 15% or greater, the head-to-head study found.

GLP-1RAs were associated with a significantly reduced risk of obesity-associated cancers including gallbladder cancer, pancreatic cancer, and meningioma.

The preserved bone mass observed in participants taking liraglutide and exercising was seen despite weight reduction levels similar to outcomes with semaglutide and tirzepatide.

This quick quiz tests what you know about updates to the 2024 ADA standards of care, which include guidance on antiobesity drugs and managing comorbid chronic disease.

ADA 2024. Adults with OSA and obesity receiving tirzepatide had improvements in sleep apnea severity and systolic blood pressure compared to placebo.